ID   VCaP-R
AC   CVCL_C0QQ
DR   cancercelllines; CVCL_C0QQ
DR   Wikidata; Q112930541
RX   PubMed=30244336;
CC   Population: Caucasian.
CC   Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI_45863; Paclitaxel (Taxol).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3446; ERG + HGNC; HGNC:11876; TMPRSS2; Name(s)=TMPRSS2-ERG (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7127; MLH1; Simple; p.Ile219Val (c.655A>G); ClinVar=VCV000036557; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone, vertebra; UBERON=UBERON_0002412.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2235 ! VCaP
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 19-12-24; Version: 7
//
RX   PubMed=30244336; DOI=10.1007/s00345-018-2501-6;
RA   Samli, Hale
RA   Samli, Murat
RA   Vatansever, Buse
RA   Ardicli, Sena
RA   Aztopal, Nazlihan
RA   Dincel, Deniz
RA   Sahin, Ahmet
RA   Balci, Faruk
RT   "Paclitaxel resistance and the role of miRNAs in prostate cancer cell
RT   lines.";
RL   World J. Urol. 37:1117-1126(2019).
//